JP2013517265A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013517265A5 JP2013517265A5 JP2012548536A JP2012548536A JP2013517265A5 JP 2013517265 A5 JP2013517265 A5 JP 2013517265A5 JP 2012548536 A JP2012548536 A JP 2012548536A JP 2012548536 A JP2012548536 A JP 2012548536A JP 2013517265 A5 JP2013517265 A5 JP 2013517265A5
- Authority
- JP
- Japan
- Prior art keywords
- matrix composition
- nucleic acid
- peg
- lipid
- methacrylate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011159 matrix material Substances 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 15
- 239000002202 Polyethylene glycol Substances 0.000 claims 11
- 108020004707 nucleic acids Proteins 0.000 claims 11
- 102000039446 nucleic acids Human genes 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 229920001223 polyethylene glycol Polymers 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 150000002632 lipids Chemical class 0.000 claims 9
- 229920002988 biodegradable polymer Polymers 0.000 claims 6
- 239000004621 biodegradable polymer Substances 0.000 claims 6
- 150000003904 phospholipids Chemical class 0.000 claims 5
- 229930182558 Sterol Natural products 0.000 claims 4
- 229920000249 biocompatible polymer Polymers 0.000 claims 4
- -1 cationic lipid Chemical class 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 150000004665 fatty acids Chemical group 0.000 claims 4
- 238000002156 mixing Methods 0.000 claims 4
- 239000000243 solution Substances 0.000 claims 4
- 150000003432 sterols Chemical class 0.000 claims 4
- 235000003702 sterols Nutrition 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- 108020004414 DNA Proteins 0.000 claims 3
- 239000003960 organic solvent Substances 0.000 claims 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 3
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 claims 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 2
- 108700011259 MicroRNAs Proteins 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 229920000954 Polyglycolide Polymers 0.000 claims 2
- 239000004793 Polystyrene Substances 0.000 claims 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 229920000229 biodegradable polyester Polymers 0.000 claims 2
- 239000004622 biodegradable polyester Substances 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 2
- 239000004633 polyglycolic acid Substances 0.000 claims 2
- 239000004626 polylactic acid Substances 0.000 claims 2
- 229920002223 polystyrene Polymers 0.000 claims 2
- 239000002244 precipitate Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- 238000013268 sustained release Methods 0.000 claims 2
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 claims 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 claims 1
- ZSZRUEAFVQITHH-UHFFFAOYSA-N 2-(2-methylprop-2-enoyloxy)ethyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CC(=C)C(=O)OCCOP([O-])(=O)OCC[N+](C)(C)C ZSZRUEAFVQITHH-UHFFFAOYSA-N 0.000 claims 1
- WDQMWEYDKDCEHT-UHFFFAOYSA-N 2-ethylhexyl 2-methylprop-2-enoate Chemical compound CCCCC(CC)COC(=O)C(C)=C WDQMWEYDKDCEHT-UHFFFAOYSA-N 0.000 claims 1
- WLZPCFOGJNCCRJ-UHFFFAOYSA-M 4-ethenyl-1-ethylpyridin-1-ium;bromide Chemical compound [Br-].CC[N+]1=CC=C(C=C)C=C1 WLZPCFOGJNCCRJ-UHFFFAOYSA-M 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims 1
- 108020004491 Antisense DNA Proteins 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 1
- 229930040373 Paraformaldehyde Natural products 0.000 claims 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 claims 1
- 239000004952 Polyamide Substances 0.000 claims 1
- 108010039918 Polylysine Proteins 0.000 claims 1
- 239000004743 Polypropylene Substances 0.000 claims 1
- 108091030071 RNAI Proteins 0.000 claims 1
- ISXSJGHXHUZXNF-LXZPIJOJSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate;hydrochloride Chemical compound Cl.C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 ISXSJGHXHUZXNF-LXZPIJOJSA-N 0.000 claims 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 1
- 239000003816 antisense DNA Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 claims 1
- 239000013611 chromosomal DNA Substances 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 229920006237 degradable polymer Polymers 0.000 claims 1
- UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 claims 1
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 claims 1
- GMSCBRSQMRDRCD-UHFFFAOYSA-N dodecyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)=C GMSCBRSQMRDRCD-UHFFFAOYSA-N 0.000 claims 1
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 230000008020 evaporation Effects 0.000 claims 1
- 235000021588 free fatty acids Nutrition 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 230000009368 gene silencing by RNA Effects 0.000 claims 1
- 239000008240 homogeneous mixture Substances 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003905 phosphatidylinositols Chemical class 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 229920002647 polyamide Polymers 0.000 claims 1
- 229920000656 polylysine Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 229920006324 polyoxymethylene Polymers 0.000 claims 1
- 229920001155 polypropylene Polymers 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- 229920002635 polyurethane Polymers 0.000 claims 1
- 239000004814 polyurethane Substances 0.000 claims 1
- 229920000915 polyvinyl chloride Polymers 0.000 claims 1
- 239000004800 polyvinyl chloride Substances 0.000 claims 1
- 239000001294 propane Substances 0.000 claims 1
- 108020004418 ribosomal RNA Proteins 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 150000003408 sphingolipids Chemical class 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 229930003799 tocopherol Natural products 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- 235000019149 tocopherols Nutrition 0.000 claims 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29604010P | 2010-01-19 | 2010-01-19 | |
| US61/296,040 | 2010-01-19 | ||
| PCT/IL2011/000054 WO2011089595A2 (en) | 2010-01-19 | 2011-01-18 | Sustained-release nucleic acid matrix compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013517265A JP2013517265A (ja) | 2013-05-16 |
| JP2013517265A5 true JP2013517265A5 (OSRAM) | 2014-03-06 |
| JP5860409B2 JP5860409B2 (ja) | 2016-02-16 |
Family
ID=44307336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012548536A Active JP5860409B2 (ja) | 2010-01-19 | 2011-01-18 | 徐放性核酸マトリックス組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8795726B2 (OSRAM) |
| EP (1) | EP2525778B1 (OSRAM) |
| JP (1) | JP5860409B2 (OSRAM) |
| CN (1) | CN102892406B (OSRAM) |
| AU (1) | AU2011208374B2 (OSRAM) |
| CA (1) | CA2783001C (OSRAM) |
| WO (1) | WO2011089595A2 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2630805T3 (es) | 2008-07-14 | 2017-08-24 | Polypid Ltd. | Composición de vehículo de fármaco de liberación sostenida |
| IN2012DN00570A (OSRAM) | 2009-07-14 | 2015-06-12 | Polypid Ltd | |
| CN103500847B (zh) * | 2013-10-02 | 2016-08-17 | 中国地质大学（武汉） | 锂硫电池添加剂、含有该添加剂的正极材料及其制备方法 |
| WO2015069870A1 (en) * | 2013-11-07 | 2015-05-14 | The University Of North Carolina At Chapel Hill | Particles containing phospholipids or bioactive fatty acid |
| US20160340659A1 (en) | 2014-01-30 | 2016-11-24 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. | Actin binding peptides and compositions comprising same for inhibiting angiogenesis and treating medical conditions associated with same |
| JP2016023148A (ja) * | 2014-07-17 | 2016-02-08 | 富士フイルム株式会社 | 脂質粒子の製造法および脂質粒子を有する核酸送達キャリア |
| SG10202012452UA (en) * | 2014-10-02 | 2021-01-28 | Polypid Ltd | Compositions and methods for the treatment and prophylaxis of surgical site infections |
| AU2018341389A1 (en) * | 2017-09-26 | 2020-04-23 | Nanomi B.V. | Method for preparing micro-particles by double emulsion technique |
| CN107823725B (zh) * | 2017-10-11 | 2020-10-09 | 上海君联医疗设备有限公司 | 一种可延期回收的血栓滤器及其制作方法 |
| JP6388700B2 (ja) * | 2017-10-20 | 2018-09-12 | 富士フイルム株式会社 | 脂質粒子の製造法および脂質粒子を有する核酸送達キャリア |
| EP3700965A1 (en) | 2017-10-27 | 2020-09-02 | Massachusetts Institute of Technology | Poly (beta-amino esters) and uses thereof |
| CN113166783B (zh) | 2018-10-09 | 2024-10-11 | 不列颠哥伦比亚大学 | 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法 |
| AU2019366996A1 (en) * | 2018-10-26 | 2021-05-27 | Massachusetts Institute Of Technology | Polymer-lipids and compositions |
| US12433847B2 (en) | 2021-03-09 | 2025-10-07 | Massachusetts Institute Of Technology | Branched poly(-amino esters) for the delivery of nucleic acids |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4522803A (en) | 1983-02-04 | 1985-06-11 | The Liposome Company, Inc. | Stable plurilamellar vesicles, their preparation and use |
| US4882167A (en) | 1983-05-31 | 1989-11-21 | Jang Choong Gook | Dry direct compression compositions for controlled release dosage forms |
| US4578384A (en) | 1984-02-15 | 1986-03-25 | The United States Of America As Represented By The Secretary Of The Army | Polylactic-polyglycolic acids combined with an acidic phospholipid-lysozyme complex for healing osseous tissue |
| JPS6163613A (ja) | 1984-09-04 | 1986-04-01 | Mitsui Toatsu Chem Inc | 顆粒状に調整された徐放性製剤 |
| US5043166A (en) | 1987-01-09 | 1991-08-27 | Hadasit Medical Research, Inc. | Liposome/anthraquinone drug composition and method |
| IL91664A (en) | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
| CA2068216C (en) | 1989-11-13 | 1999-04-13 | Abraham J. Domb | Lipospheres for controlled delivery of substances |
| US6120805A (en) | 1990-04-06 | 2000-09-19 | Rhone-Poulenc Rorer Sa | Microspheres, process for their preparation and their use |
| JPH046115A (ja) | 1990-04-25 | 1992-01-10 | Olympus Optical Co Ltd | 光学素子成形用型 |
| JPH0418035A (ja) | 1990-05-10 | 1992-01-22 | Nkk Corp | 徐放性製剤および製造法 |
| JPH0446115A (ja) | 1990-06-13 | 1992-02-17 | Eisai Co Ltd | マイクロスフィアの製造法 |
| US5922340A (en) | 1992-09-10 | 1999-07-13 | Children's Medical Center Corporation | High load formulations and methods for providing prolonged local anesthesia |
| US6180134B1 (en) | 1993-03-23 | 2001-01-30 | Sequus Pharmaceuticals, Inc. | Enhanced ciruclation effector composition and method |
| EP0804249A2 (en) | 1994-03-15 | 1997-11-05 | Brown University Research Foundation | Polymeric gene delivery system |
| US6156337A (en) | 1994-07-08 | 2000-12-05 | Opperbas Holding B.V. | Method for high loading of vesicles with biopolymeric substances |
| US6333021B1 (en) | 1994-11-22 | 2001-12-25 | Bracco Research S.A. | Microcapsules, method of making and their use |
| US6040295A (en) | 1995-01-13 | 2000-03-21 | Genemedicine, Inc. | Formulated nucleic acid compositions and methods of administering the same for gene therapy |
| US5919480A (en) | 1996-06-24 | 1999-07-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposomal influenza vaccine composition and method |
| US5837221A (en) | 1996-07-29 | 1998-11-17 | Acusphere, Inc. | Polymer-lipid microencapsulated gases for use as imaging agents |
| WO1998007412A1 (en) | 1996-08-21 | 1998-02-26 | Alkermes Controlled Therapeutics, Inc. | Controlled release microparticles with a hydrophobic material |
| ES2189974T3 (es) | 1996-09-11 | 2003-07-16 | Imarx Pharmaceutical Corp | Procedimientos mejorados para la obtencion de imagenes de diagnostico usando un agente de contraste y un vasodilatador. |
| US6048551A (en) | 1997-03-27 | 2000-04-11 | Hilfinger; John M. | Microsphere encapsulation of gene transfer vectors |
| US6248345B1 (en) | 1997-07-02 | 2001-06-19 | Euro-Celtique, S.A. | Prolonged anesthesia in joints and body spaces |
| US6287587B2 (en) | 1997-07-15 | 2001-09-11 | Takeda Chemical Industries, Ltd. | Process for producing sustained-release preparation by in-water drying |
| US6787132B1 (en) | 1997-12-04 | 2004-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combined chemo-immunotherapy with liposomal drugs and cytokines |
| US6022554A (en) * | 1997-12-15 | 2000-02-08 | American Home Products Corporation | Polymeric microporous film coated subcutaneous implant |
| AU747391B2 (en) | 1998-04-27 | 2002-05-16 | Cantab Biopharmaceuticals Patents Limited | Pharmaceutical composition comprising factor VIII and neutral liposomes |
| US6423345B2 (en) * | 1998-04-30 | 2002-07-23 | Acusphere, Inc. | Matrices formed of polymer and hydrophobic compounds for use in drug delivery |
| ATE428371T1 (de) * | 1998-07-17 | 2009-05-15 | Pacira Pharmaceuticals Inc | Biologisch abbaubare anordnungen zur kontrollierten freigabe eingeschlossener substanzen |
| WO2000003683A2 (en) * | 1998-07-20 | 2000-01-27 | Inex Pharmaceuticals Corporation | Liposomal encapsulated nucleic acid-complexes |
| DE69935435T2 (de) | 1998-08-12 | 2007-12-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Mittels Ammoniumsulfatgradient hergestellte liposomale analgetische Zusammensetzungen |
| US6153217A (en) | 1999-01-22 | 2000-11-28 | Biodelivery Sciences, Inc. | Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents |
| US6083482A (en) | 1999-05-11 | 2000-07-04 | Icn Pharmaceuticals, Inc. | Conformationally locked nucleosides and oligonucleotides |
| WO2000078358A2 (en) | 1999-06-18 | 2000-12-28 | The Collaborative Group, Ltd. | Hyaluronic acid microspheres for sustained gene transfer |
| DE10001172A1 (de) | 2000-01-13 | 2001-07-26 | Max Planck Gesellschaft | Templatieren von Feststoffpartikeln mit Polymermultischichten |
| US6967028B2 (en) | 2000-07-31 | 2005-11-22 | Mainelab | Prolonged release microspheres for injectable administration |
| IL155204A0 (en) | 2000-10-02 | 2003-11-23 | Arizeke Pharmaceuticals Inc | Compositions and methods for the transport of biologically active agents across cellular barriers |
| FI20010540A0 (fi) | 2001-03-16 | 2001-03-16 | Yli Urpo Antti | Komposiitti pehmyt- ja kovakudosvammojen korjaamiseksi ja mainitun komposiitin käyttö |
| US20020137433A1 (en) * | 2001-03-26 | 2002-09-26 | Lee Lawrence K. | Abrasive drill bit |
| EP1429745A2 (en) | 2001-09-28 | 2004-06-23 | McNEIL-PPC, INC. | Composite dosage forms having an inlaid portion |
| TWI226249B (en) | 2001-12-19 | 2005-01-11 | Ind Tech Res Inst | Biodegradable composite matrix for enhancing angiogenesis |
| AU2003237864B2 (en) | 2002-05-15 | 2008-12-18 | California Pacific Medical Center | Delivery of nucleic acid-like compounds |
| WO2004071452A2 (en) | 2003-02-12 | 2004-08-26 | Ceremed, Inc. | Random and non-random alkylene oxide polymer alloy compositions |
| EP1622540A4 (en) * | 2003-03-11 | 2009-12-30 | Qlt Usa Inc | PREPARATIONS OF ANTI-CANCER AGENTS DEPENDENT ON THE CELLULAR PROGRAM |
| GB0305941D0 (en) | 2003-03-14 | 2003-04-23 | Camurus Ab | Composition |
| KR101293002B1 (ko) | 2003-04-10 | 2013-08-02 | 데이진 가부시키가이샤 | 허니콤 구조를 갖는 생분해성 필름 |
| US20040247624A1 (en) | 2003-06-05 | 2004-12-09 | Unger Evan Charles | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
| US20060188573A1 (en) | 2003-06-10 | 2006-08-24 | Anna Imberg | Composite materials and particles |
| US20050249697A1 (en) | 2003-09-24 | 2005-11-10 | Uhrich Kathryn E | Compositions and methods for the inhibition of bone growth and resorption |
| US7915028B2 (en) | 2003-11-21 | 2011-03-29 | Teijin Limited | Tissue regeneration substrate, complex thereof with cells, and method for its production |
| WO2005070466A2 (en) * | 2004-01-15 | 2005-08-04 | Alza Corporation | Liposome composition for delivery of therapeutic agents |
| US20050181928A1 (en) * | 2004-02-12 | 2005-08-18 | Hayward Peter J. | Reaction-bonded porous magnesia body |
| US8277831B2 (en) | 2004-02-17 | 2012-10-02 | Advanced Technologies And Regenerative Medicine, Llc. | Drug-enhanced adhesion prevention |
| US7744644B2 (en) | 2004-03-19 | 2010-06-29 | Boston Scientific Scimed, Inc. | Medical articles having regions with polyelectrolyte multilayer coatings for regulating drug release |
| PL1768650T3 (pl) | 2004-06-04 | 2009-01-30 | Camurus Ab | Ciekłe formulacje depot |
| US20050287180A1 (en) | 2004-06-15 | 2005-12-29 | Chen Andrew X | Phospholipid compositions and methods for their preparation and use |
| US20060147520A1 (en) | 2004-07-26 | 2006-07-06 | Curtis Ruegg | Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation |
| CA2605000A1 (en) | 2005-04-25 | 2006-11-02 | Amgen Inc. | Biodegradable peptide sustained release compositions containing porogens |
| GB2430929A (en) * | 2005-10-04 | 2007-04-11 | Acco Uk Ltd | Apparatus for dividing a bundle of sheet material from a larger bundle |
| US20070141134A1 (en) | 2005-12-16 | 2007-06-21 | Kosak Matthew K | Shielded micelles for polynucleotide delivery |
| US20090318355A1 (en) | 2006-02-15 | 2009-12-24 | Chen Thomas T | Compositions and methods for promoting tissue repair and wound healing |
| ES2776100T3 (es) | 2006-03-31 | 2020-07-29 | Massachusetts Inst Technology | Sistema para el suministro dirigido de agentes terapéuticos |
| US8703167B2 (en) | 2006-06-05 | 2014-04-22 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable medical devices for controlled release of a hydrophilic drug and a hydrophobic drug |
| US20080181928A1 (en) * | 2006-12-22 | 2008-07-31 | Miv Therapeutics, Inc. | Coatings for implantable medical devices for liposome delivery |
| WO2008108286A1 (ja) | 2007-03-02 | 2008-09-12 | Teika Pharmaceutical Co., Ltd. | 経皮吸収医薬組成物、医薬組成物貯蔵ユニットおよびこれを利用する経皮吸収製剤 |
| WO2008124634A1 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Polymer-encapsulated reverse micelles |
| US20100210575A1 (en) | 2007-06-29 | 2010-08-19 | Wisconsin Alumni Research Foundation | Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals |
| US20090110713A1 (en) | 2007-10-31 | 2009-04-30 | Florencia Lim | Biodegradable polymeric materials providing controlled release of hydrophobic drugs from implantable devices |
| US20100285111A1 (en) | 2007-11-09 | 2010-11-11 | Northeastern University | Self-assembling micelle-like nanoparticles for systemic gene delivery |
| US20110027172A1 (en) * | 2007-12-10 | 2011-02-03 | Zhuang Wang | Drug delivery system for pharmaceuticals and radiation |
| US8128983B2 (en) * | 2008-04-11 | 2012-03-06 | Abbott Cardiovascular Systems Inc. | Coating comprising poly(ethylene glycol)-poly(lactide-glycolide-caprolactone) interpenetrating network |
| CA2721333C (en) | 2008-04-15 | 2020-12-01 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
| WO2010001325A2 (en) * | 2008-06-30 | 2010-01-07 | Silenseed Ltd | Methods, compositions and systems for local delivery of drugs |
| ES2630805T3 (es) | 2008-07-14 | 2017-08-24 | Polypid Ltd. | Composición de vehículo de fármaco de liberación sostenida |
| WO2010078517A2 (en) | 2008-12-31 | 2010-07-08 | Sirnaomics, Inc. | Compositions and methods using sirna molecules and sirna cocktails for the treatment of breast cancer |
| WO2010135207A1 (en) | 2009-05-16 | 2010-11-25 | Agave Pharma, Incorporated | Compositions comprising cationic amphiphiles and colipids for delivering therapeutics molecules |
| IN2012DN00570A (OSRAM) | 2009-07-14 | 2015-06-12 | Polypid Ltd |
-
2011
- 2011-01-18 JP JP2012548536A patent/JP5860409B2/ja active Active
- 2011-01-18 CA CA2783001A patent/CA2783001C/en active Active
- 2011-01-18 CN CN201180006572.5A patent/CN102892406B/zh active Active
- 2011-01-18 EP EP11734448.1A patent/EP2525778B1/en active Active
- 2011-01-18 WO PCT/IL2011/000054 patent/WO2011089595A2/en not_active Ceased
- 2011-01-18 AU AU2011208374A patent/AU2011208374B2/en active Active
- 2011-01-18 US US13/574,040 patent/US8795726B2/en active Active
-
2014
- 2014-08-04 US US14/450,310 patent/US9616032B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013517265A5 (OSRAM) | ||
| Zhu et al. | RNA-based therapeutics: an overview and prospectus | |
| Winkle et al. | Noncoding RNA therapeutics—challenges and potential solutions | |
| EP2323630B1 (en) | Methods, compositions and systems for local delivery of drugs | |
| JP2011526619A5 (OSRAM) | ||
| Adams et al. | Targeting noncoding RNAs in disease | |
| MacLeod et al. | RNA therapeutics in oncology: advances, challenges, and future directions | |
| Li et al. | Recent advances in targeted delivery of non-coding RNA-based therapeutics for atherosclerosis | |
| Rayburn et al. | Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? | |
| Rujitanaroj et al. | Nanofiber-mediated controlled release of siRNA complexes for long term gene-silencing applications | |
| EP3399039B1 (en) | Compounds for treatment of ischemic injury | |
| Kwekkeboom et al. | Targeted delivery of miRNA therapeutics for cardiovascular diseases: opportunities and challenges | |
| JP5860409B2 (ja) | 徐放性核酸マトリックス組成物 | |
| Chin et al. | Scaffold-mediated non-viral delivery platform for CRISPR/Cas9-based genome editing | |
| JP2017217007A (ja) | ロックド核酸モチーフを含むオリゴヌクレオチドベースの阻害剤 | |
| RU2668794C2 (ru) | Композиция, содержащая инкапсулированный антагомир | |
| US20120083037A1 (en) | Non-Viral Transfection Agent | |
| JP2013514977A5 (OSRAM) | ||
| CN101821391A (zh) | 微小聚体 | |
| JP2015521626A5 (OSRAM) | ||
| AU2023201262A1 (en) | Amphiregulin gene-specific double-stranded oligonucleotide and composition for preventing and treating fibrosis-related diseases and respiratory diseases, comprising same | |
| JP2014521636A5 (OSRAM) | ||
| JP2016506923A5 (OSRAM) | ||
| Chakraborty et al. | Therapeutic microRNA delivery strategies with special emphasis on cancer therapy and tumorigenesis: current trends and future challenges | |
| Fathi-Azarbayjani et al. | Single and multi-layered nanofibers for rapid and controlled drug delivery |